Search Results - "TEUNISSEN, Jaap J"

Long-Term Efficacy, Survival, and Safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors by Brabander, Tessa, van der Zwan, Wouter A, Teunissen, Jaap J M, Kam, Boen L R, Feelders, Richard A, de Herder, Wouter W, van Eijck, Casper H J, Franssen, Gaston J H, Krenning, Eric P, Kwekkeboom, Dik J

“…Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell…”
Get full text

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate by Forrer, Flavio, Krenning, Eric P., Kooij, Peter P., Bernard, Bert F., Konijnenberg, Mark, Bakker, Willem H., Teunissen, Jaap J. M., de Jong, Marion, van Lom, Kirsten, de Herder, Wouter W., Kwekkeboom, Dik J.

“…Purpose Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a…”
Get full text

Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors by KWEKKEBOOM, Dik J, TEUNISSEN, Jaap J, BAKKER, Willem H, KOOIJ, Peter P, DE HERDER, Wouter W, FEELDERS, Richard A, VAN EIJCK, Casper H, ESSER, Jan-Paul, KAM, Boen L, KRENNING, Eric P

“…There are few treatment options for patients with metastasized or inoperable endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but…”
Get full text

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors by Kwekkeboom, Dik J, Kam, Boen L, van Essen, Martijn, Teunissen, Jaap J M, van Eijck, Casper H J, Valkema, Roelf, de Jong, Marion, de Herder, Wouter W, Krenning, Eric P

“…Somatostatin receptor imaging (SRI) with [111In-DTPA0]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine…”
Get full text

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial) by Braat, Arthur J. A. T, Kwekkeboom, Dik J, Kam, Boen L. R, Teunissen, Jaap J. M, de Herder, Wouter W, Dreijerink, Koen M. A, van Rooij, Rob, Krijger, Gerard C, de Jong, Hugo W. A. M, van den Bosch, Maurice A. A. J, Lam, Marnix G. E. H

“…Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a…”
Get full text

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy by van Vliet, Esther I, Teunissen, Jaap J M, Kam, Boen L R, de Jong, Marion, Krenning, Eric P, Kwekkeboom, Dik J

“…The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of…”
Get more information

Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function by Teunissen, Jaap J. M., Krenning, Eric P., de Jong, Frank H., de Rijke, Yolanda B., Feelders, Richard A., van Aken, Maarten O., de Herder, Wouter W., Kwekkeboom, Dik J.

“…Purpose Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues is a novel therapy for patients with somatostatin…”
Get full text

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour by da Silva, Tiago Nunes, van Velthuysen, M L F, van Eijck, Casper H J, Teunissen, Jaap J, Hofland, J, de Herder, Wouter W

“…Summary Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of…”
Get full text

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs by Bergsma, Hendrik, MD, PhD, van Vliet, Esther I., MD, PhD, Teunissen, Jaap J.M., MD, PhD, Kam, Boen L.R., MD, de Herder, Wouter W., MD, PhD, Peeters, Robin P., MD, PhD, Krenning, Eric P., MD, PhD, Kwekkeboom, Dik J., MD, PhD

“…Abstract Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with…”
Get full text

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate by van Vliet, Esther I., de Herder, Wouter W., de Rijke, Yolanda B., Zillikens, M. Carola, Kam, Boen L. R., Teunissen, Jaap J. M., Peeters, Robin P., Krenning, Eric P., Kwekkeboom, Dik J.

“…Purpose The aim of this study was to explore the possible mechanisms involved in an observed decline in serum calcium levels in patients with a neuroendocrine…”
Get full text

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments by Bison, Sander M., Konijnenberg, Mark W., Melis, Marleen, Pool, Stefan E., Bernsen, Monique R., Teunissen, Jaap J. M., Kwekkeboom, Dik J., de Jong, Marion

“…Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment for neuroendocrine tumors (NETs) if curative surgery is not an option…”
Get full text

Clinical Pharmacology of Radiotheranostics in Oncology by te Beek, Erik T., Burggraaf, Jacobus, Teunissen, Jaap J. M., Vriens, Dennis

“…The combined use of diagnostic and therapeutic radioligands with the same molecular target, also known as theranostics, enables accurate patient selection,…”
Get full text

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate by Khan, Saima, Krenning, Eric P, van Essen, Martijn, Kam, Boen L, Teunissen, Jaap J, Kwekkeboom, Dik J

“…Quality of life (QOL) is an important outcome in cancer therapy. In this study, we investigated the QOL and symptoms after [(177)Lu-DOTA(0),Tyr(3)]octreotate…”
Get full text

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours by Teunissen, Jaap J M, Kwekkeboom, Dik J, Valkema, R, Krenning, Eric P

“…Nuclear medicine plays a pivotal role in the imaging and treatment of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy (SRS) with…”
Get full text

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate by van Vliet, Esther I, van Eijck, Casper H, de Krijger, Ronald R, Nieveen van Dijkum, Elisabeth J, Teunissen, Jaap J, Kam, Boen L, de Herder, Wouter W, Feelders, Richard A, Bonsing, Bert A, Brabander, Tessa, Krenning, Eric P, Kwekkeboom, Dik J

“…Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for which surgery has almost the only potential for cure. When surgery is not possible because of…”
Get full text

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate by Brabander, Tessa, van der Zwan, Wouter A, Teunissen, Jaap J M, Kam, Boen L R, de Herder, Wouter W, Feelders, Richard A, Krenning, Eric P, Kwekkeboom, Dik J

“…Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic…”
Get full text

Precision medicine and theranostics using radiopharmaceuticals in oncology by Beek, Erik T., Teunissen, Jaap J. M., Postema, Jan W. A., Lafeber, Albert, Broek, Marc R. J.

Get full text

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate by van Vliet, Esther I, Krenning, Eric P, Teunissen, Jaap J, Bergsma, Hendrik, Kam, Boen L, Kwekkeboom, Dik J

“…Response Evaluation Criteria In Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and…”
Get full text

Peptide receptor radionuclide therapy of neuroendocrine tumours by Brabander, Tessa, MD, Teunissen, Jaap J.M., MD, PhD, Van Eijck, Casper H.J., MD, PhD, Franssen, Gaston J.H., MD, Feelders, Richard A., MD, PhD, de Herder, Wouter W., MD, PhD, Kwekkeboom, Dik J., MD, PhD

“…In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised…”
Get full text

Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors by Kwekkeboom, Dik J., MD, PhD, de Herder, Wouter W., MD, PhD, van Eijck, Casper H.J., MD, PhD, Kam, Boen L., MD, van Essen, Martijn, MD, Teunissen, Jaap J.M., MD, PhD, Krenning, Eric P., MD, PhD

“…Somatostatin receptor imaging with [111 In-DTPA0 )octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors…”
Get full text